Trulieve Cannabis (TRLV) EBITDA Margin (2020 - 2026)
Trulieve Cannabis (TRLV) posted quarterly EBITDA Margin of 12.46% for Q1 2026, up 127.0% year-over-year from 5.49% in Q1 2025, and up 138.75% quarter-over-quarter from 5.22% in Q4 2025.
Trulieve Cannabis (TRLV) EBITDA Margin (2020 - 2026) Analysis & Trends
Trulieve Cannabis' EBITDA Margin history runs 7 years deep, the most recent figure standing at 12.46% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 127.0% year-over-year to 12.46%; the TTM figure through Mar 2026 stood at 12.47% (up 530.0% YoY), while the FY2025 annual figure was 12.15%, up 391.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 12.46%, up from 5.22% in the prior quarter.
- The five-year high for EBITDA Margin was 17.42% in Q2 2025, with the low at 103.37% in Q2 2023.
- The 5-year median for EBITDA Margin is 9.18% (2022), against an average of 1.75%.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin tumbled 11658 bps in 2023, then soared 11977 bps in 2024.
- Trulieve Cannabis' EBITDA Margin stood at 1.74% in 2022, then soared by 483 bps to 10.17% in 2023, then sank by 96 bps to 0.43% in 2024, then jumped by 1101 bps to 5.22% in 2025, then jumped by 139 bps to 12.46% in 2026.
- Business Quant data shows TRLV's EBITDA Margin at 12.46% in Q1 2026, 5.22% in Q4 2025, and 14.66% in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -136.75% |
| Mar 31, 2026 | 12.46% |
| Dec 31, 2025 | 5.22% |
| Sep 30, 2025 | 14.66% |
| Jun 30, 2025 | 17.42% |
| Mar 31, 2025 | 11.19% |
| Dec 31, 2024 | 0.43% |
| Sep 30, 2024 | 0.22% |
| Jun 30, 2024 | 16.40% |
| Mar 31, 2024 | 15.49% |
| Dec 31, 2023 | 10.17% |
| Sep 30, 2023 | 8.48% |
| Jun 30, 2023 | -103.37% |
| Mar 31, 2023 | 6.01% |
| Dec 31, 2022 | 1.74% |
| Sep 30, 2022 | -9.26% |
| Jun 30, 2022 | 13.22% |
| Mar 31, 2022 | 9.18% |
| Dec 31, 2021 | -3.71% |
| Sep 30, 2021 | 29.57% |